$DWTX
Dogwood Therapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000155837022013410 Filed on August 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $970.0K $1.266M $1.192M
YoY Change -15.68% 17.7% -11.7%
% of Gross Profit
Research & Development $1.622M $2.406M $2.769M
YoY Change -45.21% -25.01% 62.22%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.592M $3.672M $3.961M
YoY Change -36.95% -14.29% 29.56%
Operating Profit -$2.592M -$3.672M -$3.961M
YoY Change -36.95% -14.29% 29.56%
Interest Expense $16.61K $4.800K $910.00
YoY Change 1000.0% 220.0%
% of Operating Profit
Other Income/Expense, Net $16.61K $4.804K $906.00
YoY Change 1000.4% 221.34% -35.29%
Pretax Income -$2.576M -$3.667M -$3.960M
YoY Change -37.33% -14.38% 29.59%
Income Tax
% Of Pretax Income
Net Earnings -$2.576M -$3.667M -$3.960M
YoY Change -37.33% -14.38% 29.59%
Net Earnings / Revenue
Basic Earnings Per Share -$0.28 -$0.44 -$0.48
Diluted Earnings Per Share -$0.28 -$0.44 -$0.48
COMMON SHARES
Basic Shares Outstanding 8.330M 8.330M 8.330M
Diluted Shares Outstanding 9.200M 8.330M 8.330M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.788M $7.695M $11.35M
YoY Change -48.98% -64.76% -53.83%
Cash & Equivalents $9.788M $7.695M $11.35M
Short-Term Investments
Other Short-Term Assets $1.070M $1.345M $1.198M
YoY Change 16.14% -30.3% -67.54%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $10.86M $9.040M $12.55M
YoY Change -46.0% -61.96% -55.61%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $10.86M $9.040M $12.55M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $10.86M $9.040M $12.55M
YoY Change -46.0% -61.96% -55.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $679.4K $665.5K $330.7K
YoY Change 40.52% 153.45% -46.2%
Accrued Expenses $953.7K $1.232M $1.547M
YoY Change 28.31% 91.43% 179.84%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.633M $1.898M $1.877M
YoY Change 33.12% 109.4% 60.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.633M $1.898M $1.877M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.633M $1.898M $1.877M
YoY Change 33.12% 109.4% 60.82%
SHAREHOLDERS EQUITY
Retained Earnings -$54.13M -$51.55M -$47.89M
YoY Change 37.38% 46.04% 54.47%
Common Stock $1.833K $833.00 $833.00
YoY Change 120.05% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.225M $7.142M $10.67M
YoY Change
Total Liabilities & Shareholders Equity $10.86M $9.040M $12.55M
YoY Change -46.0% -61.96% -55.61%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$2.576M -$3.667M -$3.960M
YoY Change -37.33% -14.38% 29.59%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.483M -$3.657M -$2.656M
YoY Change -6.25% 32.86% -48.05%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.577M 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -2.483M -3.657M -2.656M
Cash From Investing Activities
Cash From Financing Activities 4.577M 0.000 0.000
Net Change In Cash 2.093M -3.657M -2.656M
YoY Change -179.03% 32.97% -49.02%
FREE CASH FLOW
Cash From Operating Activities -$2.483M -$3.657M -$2.656M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8330390
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8330390
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8330390
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8328212
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001818844
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8330390
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8330390
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.92
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39811
dei Entity Registrant Name
EntityRegistrantName
Virios Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-4314201
dei Entity Address Address Line1
EntityAddressAddressLine1
44 Milton Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
Alpharetta
dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30009
dei City Area Code
CityAreaCode
866
dei Local Phone Number
LocalPhoneNumber
620-8655
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
VIRI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8330390
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7695040
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14008184
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1345055
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1768503
CY2022Q2 us-gaap Assets Current
AssetsCurrent
9040095
CY2021Q4 us-gaap Assets Current
AssetsCurrent
15776687
CY2022Q2 us-gaap Assets
Assets
9040095
CY2021Q4 us-gaap Assets
Assets
15776687
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
665538
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
353863
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1232193
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
921760
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1897731
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1275623
CY2022Q2 us-gaap Liabilities
Liabilities
1897731
CY2021Q4 us-gaap Liabilities
Liabilities
1275623
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8330390
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8330390
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
833
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
833
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
58694467
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
58425604
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-51552936
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-43925373
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
7142364
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
14501064
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9040095
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15776687
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2406438
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3209201
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5175540
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4916159
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1265621
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1075256
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2457733
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2425732
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
3672059
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
4284457
us-gaap Operating Expenses
OperatingExpenses
7633273
us-gaap Operating Expenses
OperatingExpenses
7341891
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3672059
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4284457
us-gaap Operating Income Loss
OperatingIncomeLoss
-7633273
us-gaap Operating Income Loss
OperatingIncomeLoss
-7341891
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4804
CY2021Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1495
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5710
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2896
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4804
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1495
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5710
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2896
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3667255
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4282962
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7627563
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7338995
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3667255
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-4282962
us-gaap Net Income Loss
NetIncomeLoss
-7627563
us-gaap Net Income Loss
NetIncomeLoss
-7338995
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.92
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8330390
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8330390
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8330390
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8328212
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
14501064
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
131906
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3960308
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
10672662
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
136957
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3667255
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
7142364
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
29940889
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24825
CY2021Q1 viri Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
197562
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3056033
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
27107243
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34244
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-4282962
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
22858525
us-gaap Profit Loss
ProfitLoss
-7627563
us-gaap Profit Loss
ProfitLoss
-7338995
us-gaap Share Based Compensation
ShareBasedCompensation
268863
us-gaap Share Based Compensation
ShareBasedCompensation
59069
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-423448
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
252325
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
311675
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
178734
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
310433
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-130320
us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
-378833
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6313144
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7862670
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
197562
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
295166
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-97604
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6313144
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7960274
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14008184
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29795366
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7695040
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21835092
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3667255
us-gaap Net Income Loss
NetIncomeLoss
-7627563
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-4282962
us-gaap Net Income Loss
NetIncomeLoss
-7338995
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6313144
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7862670
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-51552936
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of these financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include estimated work performed but not yet billed by contract manufacturers, engineers and research organizations, the valuation of equity and stock-based related instruments, and the valuation allowance related to deferred taxes. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Actual results could differ from those estimates.</p>
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
663921
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1329385
CY2022Q2 viri Prepaid Clinical Research Costs
PrepaidClinicalResearchCosts
633124
CY2021Q4 viri Prepaid Clinical Research Costs
PrepaidClinicalResearchCosts
422591
CY2022Q2 viri Prepaid Services
PrepaidServices
22632
CY2021Q4 viri Prepaid Services
PrepaidServices
15664
CY2022Q2 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
25378
CY2021Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
863
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1345055
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1768503
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
346496
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
532678
CY2022Q2 viri Accrued Interest On Preferred Members Interest
AccruedInterestOnPreferredMembersInterest
188085
CY2021Q4 viri Accrued Interest On Preferred Members Interest
AccruedInterestOnPreferredMembersInterest
188085
CY2022Q2 viri Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
667321
CY2021Q4 viri Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
138522
CY2021Q4 viri Accrued Director Fees Current
AccruedDirectorFeesCurrent
31000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
17800
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
24100
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
12491
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7375
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1232193
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
921760
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
172500
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.50
viri Warrants Exercisable Percentage
WarrantsExercisablePercentage
1
CY2022Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P3Y5M19D
CY2022Q2 viri Warrants And Rights Intrinsic Value
WarrantsAndRightsIntrinsicValue
0
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
0
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
17956000
CY2022Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0

Files In Submission

Name View Source Status
0001558370-22-013410-index-headers.html Edgar Link pending
0001558370-22-013410-index.html Edgar Link pending
0001558370-22-013410.txt Edgar Link pending
0001558370-22-013410-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20220630.xsd Edgar Link pending
tmb-20220630x10q.htm Edgar Link pending
tmb-20220630xex31d1.htm Edgar Link pending
tmb-20220630xex31d2.htm Edgar Link pending
tmb-20220630xex32d1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
tmb-20220630xex32d2.htm Edgar Link pending
tmb-20220630_cal.xml Edgar Link unprocessable
tmb-20220630_pre.xml Edgar Link unprocessable
tmb-20220630_def.xml Edgar Link unprocessable
tmb-20220630_lab.xml Edgar Link unprocessable
tmb-20220630x10q_htm.xml Edgar Link completed